日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

SWOG S0777 随机 III 期试验的长期随访：硼替佐米、来那度胺和地塞米松与来那度胺和地塞米松治疗既往未接受治疗的多发性骨髓瘤患者（Pts），且不打算立即进行自体干细胞移植（ASCT）。

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-020-0311-8
Durie, Brian G M; Hoering, Antje; Sexton, Rachael; Abidi, Muneer H; Epstein, Joshua; Rajkumar, S Vincent; Dispenzieri, Angela; Kahanic, Stephen P; Thakuri, Mohan C; Reu, Frederic J; Reynolds, Christopher M; Orlowski, Robert Z; Barlogie, Bart
发育与干细胞
多发性骨髓瘤
骨髓瘤
ASC
干细胞
细胞生物学
发表日期：2020
文献求助 收藏

Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)

早期乳腺癌紫杉醇-曲妥珠单抗辅助治疗的试点试验：ECOG-ACRIN癌症研究组的一项试验（E2198）

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/bjc.2015.405
Schneider, Bryan P; O'Neill, Anne; Shen, Fei; Sledge, George W; Thor, Ann D; Kahanic, Stephen P; Zander, Paul J; Davidson, Nancy E
肿瘤免疫
肿瘤
乳腺癌
发表日期：2015
文献求助 收藏

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer

RC0639：紫杉醇、曲妥珠单抗和拉帕替尼作为早期HER2阳性乳腺癌辅助治疗的II期研究

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-013-2469-2
Moreno-Aspitia, Alvaro; Dueck, Amylou C; Ghanem-Cañete, Ismael; Patel, Tejal; Dakhil, Shaker; Johnson, David; Franco, Sandra; Kahanic, Stephen; Colon-Otero, Gerardo; Tenner, Kathleen S; Rodeheffer, Richard; McCullough, Ann E; Jenkins, Robert B; Palmieri, Frances M; Northfelt, Donald; Perez, Edith A
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2013
文献求助 收藏

Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia

一项III期随机研究，旨在评估肠外补铁、口服补铁或不补铁对化疗相关性贫血患者接受达贝泊汀α治疗后红细胞生成反应的影响

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2010.30.3644
Steensma, David P; Sloan, Jeff A; Dakhil, Shaker R; Dalton, Robert; Kahanic, Stephen P; Prager, Diane J; Stella, Philip J; Rowland, Kendrith M Jr; Novotny, Paul J; Loprinzi, Charles L
红细胞
细胞生物学
贫血
代谢
发表日期：2011
文献求助 收藏

North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer

北中部癌症治疗协作组 (NCCTG) N0432：多西他赛联合卡培他滨和贝伐单抗作为转移性乳腺癌患者一线化疗的 II 期试验

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdp512
Perez, E A; Hillman, D W; Dentchev, T; Le-Lindqwister, N A; Geeraerts, L H; Fitch, T R; Liu, H; Graham, D L; Kahanic, S P; Gross, H M; Patel, T A; Palmieri, F M; Dueck, A C
肿瘤
肿瘤免疫
乳腺癌
发表日期：2010
文献求助 收藏

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

在接受他莫昔芬治疗后开始服用来曲唑的绝经后乳腺癌患者中，立即使用唑来膦酸与延迟使用唑来膦酸预防骨质流失的比较-N03CC

期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-009-0332-2
Hines, Stephanie L; Mincey, Betty; Dentchev, Todor; Sloan, Jeff A; Perez, Edith A; Johnson, David B; Schaefer, Paul L; Alberts, Steve; Liu, Heshan; Kahanic, Stephen; Mazurczak, Miroslaw A; Nikcevich, Daniel A; Loprinzi, Charles L
肿瘤
肿瘤免疫
乳腺癌
发表日期：2009
文献求助 收藏

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)

四环素预防表皮生长因子受体抑制剂引起的皮疹：来自北中部癌症治疗组（N03CB）的安慰剂对照试验结果

期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.23621
Jatoi, Aminah; Rowland, Kendrith; Sloan, Jeff A; Gross, Howard M; Fishkin, Paul A; Kahanic, Stephen P; Novotny, Paul J; Schaefer, Paul L; Johnson, David B; Tschetter, Loren K; Loprinzi, Charles L
信号转导
肿瘤
肿瘤免疫
发表日期：2008
文献求助 收藏